TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
INO

Inovio Pharmaceuticals Inc

Healthcare · Biotechnology

1.20$ -4.1% vs. previous close Closing price · As of: Oct 2, 2026

Statements

Balance Sheet

Inovio Pharmaceuticals Inc (INO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 49 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet INO
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
195 174 153 159 204 187 174 149 141 131 191 165 152 144 339 443 438 540 655 592 536 496 446 459 392 349 267 233 193 171 129 134 107 113 87 68 69 74 50 49
140 125 107 107 155 138 124 102 94 88 135 111 99 94 276 382 377 471 588 542 487 448 400 416 350 315 234 203 175 153 112 118 91 98 72 53 55 61 39 40
23 19 23 24 23 24 38 15 19 24 21 20 16 22 158 215 179 251 84 59 68 71 59 41 22 46 28 53 19 14 20 34 22 66 40 24 37 44 26 32
120 105 90 92 142 127 113 96 85 81 128 106 94 90 270 372 337 412 519 444 395 401 360 348 282 253 224 195 167 145 106 110 85 94 68 48 51 59 38 37
17 17 11 8.7 7.2 6.5 7.4 2.7 4.4 4.1 4.1 1.1 1.8 2.0 1.3 4.0 8.2 19 10 14 7.1 8.0 7.5 11 2.4 12 5.0 5.1 2.1 2.4 2.6 1.8 1.9 1.2 1.3 0.8 1.0 0.0 – –
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – 3.2 – – – – 86,576 – – – – – – –
9.0 9.0 9.8 15 18 18 17 17 16 16 15 14 14 13 12 11 11 11 11 30 18 17 17 16 16 7.7 7.0 6.3 15 – – – – – – – – – – –
11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 11 0.0 0.0 – – – – – – – – – –
8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.3 5.0 4.8 4.5 4.2 4.0 3.7 3.6 3.4 3.3 3.1 3.0 2.9 2.8 2.6 2.5 2.4 2.2 2.1 2.0 – – – – – – – – – – – – –
48 50 47 35 42 45 61 37 37 44 110 109 115 139 151 257 114 79 73 83 82 96 90 162 125 126 67 64 55 54 35 37 34 45 36 40 77 50 44 45
41 44 40 27 33 35 51 28 28 35 27 24 20 32 32 38 41 42 42 52 51 66 59 131 95 97 55 52 44 43 23 26 23 35 27 32 70 44 38 40
7.6 20 6.5 7.9 8.7 25 9.4 14 – – 1.9 1.9 2.0 2.1 2.1 2.2 2.3 2.3 2.4 2.5 2.5 2.6 2.7 2.7 2.8 2.8 19 19 19 19 2.2 2.3 2.4 2.5 2.6 2.7 2.7 2.8 2.9 2.9
17 7.0 15 17 23 8.5 17 13 18 11 17 14 10 7.6 11 18 24 1.5 27 32 29 28 40 40 74 21 13 10 3.9 4.6 8.3 6.4 5.4 6.4 5.5 5.5 5.9 2.6 2.0 12
0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – 61 63 75 77 99 199 54 19 14 15 14 15 16 17 16 17 – – – – – – – – – – – – – –
147 123 106 123 162 142 113 111 104 87 78 54 34 3.4 184 186 324 461 582 509 454 400 355 298 267 222 199 169 138 117 94 97 74 69 51 29 -7.7 24 6.1 4.4
-409 -435 -458 -468 -502 -523 -555 -562 -587 -620 -650 -679 -702 -740 -772 -901 -882 -906 -961 -1,043 -1,103 -1,210 -1,287 -1,396 -1,433 -1,488 -1,528 -1,564 -1,598 -1,623 -1,653 -1,686 -1,711 -1,730 -1,750 -1,773 -1,819 -1,815 -1,835 -1,841
6.1 6.2 6.2 6.3 7.3 7.7 7.5 7.6 7.7 7.9 8.1 8.2 8.6 8.3 125 156 15 16 17 17 18 18 18 20 249 21 22 22 22 23 23 27 28 32 39 39 52 69 69 82

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?